Review Article

Getting to the Heart of the Matter: Myocardial Injury, Coagulopathy, and Other Potential Cardiovascular Implications of COVID-19

Aaron Schmid, Marija Petrovic, Kavya Akella, Anisha Pareddy, and Sumathilatha Sakthi Velavan

Division of Biomedical Sciences, Marian University College of Osteopathic Medicine, Indianapolis, USA

Correspondence should be addressed to Aaron Schmid; aschmid310@marian.edu and Sumathilatha Sakthi Velavan; ssakthivelavan@marian.edu

Received 15 December 2020; Revised 30 March 2021; Accepted 8 April 2021; Published 6 May 2021

Academic Editor: Antonio Bozzani

Copyright © 2021 Aaron Schmid et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

COVID-19 was primarily identified as a respiratory illness, but reports of patients presenting initially with cardiovascular complaints are rapidly emerging. Many patients also develop cardiovascular complications during and after COVID-19 infection. Underlying cardiovascular disease increases the severity of COVID-19 infection; however, it is unclear if COVID-19 increases the risk of or causes cardiovascular complications in patients without preexisting cardiovascular disease. The review is aimed at informing the primary care physicians of the potential cardiovascular complications, especially in patients without underlying cardiovascular disease. A comprehensive literature review was performed on cardiac and vascular complications of COVID-19. The primary cardiac and vascular complications include myocarditis, acute coronary syndrome, myocardial injury, arrhythmia, heart failure, shock, multisystem inflammatory syndrome, venous and arterial thrombotic events, stroke, and coagulopathy. A detailed analysis of the pathogenesis revealed six possible mechanisms: direct cardiac damage, hypoxia-induced injury, inflammation, a dysfunctional endothelial response, coagulopathy, and the catecholamine stress response. Autopsy reports from studies show cardiomegaly, hypertrophy, ventricular dilation, infarction, and fibrosis. A wide range of cardiac and vascular complications should be considered when treating patients with confirmed or suspected COVID-19 infection. Elevated troponin and natriuretic peptides indicate an early cardiac involvement in COVID-19. Continuous monitoring of coagulation by measuring serum D-dimer can potentially prevent vascular complications. A long-term screening protocol to follow-up the patients in the primary care settings is needed to follow-up with the patients who recovered from COVID cardiovascular complications.

1. Introduction

The World Health Organization (WHO) describes coronaviruses as a group of viruses, several of which infect humans, which usually cause respiratory disease or illness, ranging from the common cold to severe acute respiratory distress syndrome (ARDS) [1]. The most recently discovered coronavirus, SARS-CoV-2, causes the infectious disease COVID-19, a pandemic affecting many countries around the world [1]. COVID-19 typically presents clinically as fever, dry cough, dyspnea, and fatigue, but signs and symptoms vary widely [1]. Reports are emerging of patients presenting with cardiovascular symptoms, including chest tightness and heart palpitations [2, 3]. Some patients present exclusively with cardiac complaints and do not have any other respiratory complaints [3]. Underlying cardiovascular disease increases the risk of severe COVID-19 disease and death [4, 5], but does COVID-19 infection increase the risk of, or cause, cardiovascular complications or cardiovascular disease in patients without underlying cardiovascular disease?

Dweck et al. (2020) demonstrated that the cardiovascular system seems to be one of the most common organ systems affected by COVID-19. After excluding patients with preexisting ischemic heart disease, heart failure, and valvular heart
disease, 46% of patients with COVID-19 with an indication for echocardiography (suspected left ventricular failure, suspected right heart failure, and elevated cardiac biomarkers) had echocardiographic abnormalities including myocardial infarction, myocarditis, and Takotsubo cardiomyopathy [6]. Another study showed 50% of COVID-19 patients had electrocardiographic abnormalities, and 42% experienced chest pain, palpitations, or dyspnea [7]. In the same study, 75% of cases in the same study had cardiac magnetic resonance (CMR) abnormalities [7]. These complications are consistent with previous case reports [8–10]. COVID-19 triggers several cardiac sequelae, including myocardial injury, acute coronary syndromes, myocarditis, arrhythmias, and acute onset heart failure [11–14]. The overall incidence of cardiac injury caused by COVID-19 varies from 7–64%, depending on the parameter used, among hospitalized patients in various reports [6, 7, 11–13].

COVID-19 can also manifest as vasculopathy. Recent studies have shown the impact that COVID-19 has had on increasing the risk of coagulopathies, including thrombotic events such as deep venous thrombosis (DVT), coagulopathy, and stroke [15–18]. General risks for coagulopathy and pathogenesis of thrombosis include age, acute illness, being bedridden, stasis, genetics, fever, diarrhea, sepsis, liver injury, CKD, COPD, HF, and malignancy [19].

This review intends to provide the primary care physicians with concise knowledge of potential cardiovascular complications in COVID-19 patients to understand the disease course better and decide how to manage and treat patients. Major common cardiac and vascular complications in COVID-19 patients were investigated, with an emphasis on those without known underlying cardiovascular disease. The authors expect this review will contribute to the intake and management of patients with suspected and confirmed COVID-19 infection making evaluation and treatment safer and more efficient. The aim is to ensure physicians are up to date on the cardiovascular complications that can arise from COVID-19.

2. Main Text

2.1. Pathogenesis of COVID-19 Cardiovascular Disease. The exact mechanism by which COVID-19 causes myocardial injury and damage is being investigated. Kim et al. proposed six different mechanisms by which COVID-19 infection may cause cardiovascular injury and manifestations [20]. These mechanisms do not individually explain the cardiac injury caused by COVID-19, but rather multiple factors affect the cardiovascular system in different ways.

(1) Direct Cardiac Damage Mediated via an Angiotensin-Converting Enzyme (ACE-2) Receptor-Dependent Myocardial Infection [20]. ACE-2 receptors are expressed in the heart, more highly expressed than in the lungs [21], and the SARS-CoV-2 virus binds and utilizes these receptors. Also, this virus can decrease angiotensin 1-7 levels, which play a protective role against cardiovascular complications [22].

(2) Hypoxia-Induced Injury from Oxidative Stress, Acidosis, and Mitochondrial Damage [20]. Researchers built on the idea of hypoxia-induced cardiac injury stating that the common manifestation of respiratory distress caused by COVID-19 infection can result in hypoxemia leading to an oxygen supply and demand mismatch [23, 24]. Hypoxemia arising from COVID-19-induced lung injury may lead to injury of cardiomyocytes as hypoxia can cause accumulation of metabolites, including oxygen free radicals [25].

(3) Inflammation Leading to Vessel Hyperpermeability and Angiospasm, Causing Microvascular Damage to the Heart [20]. A dysfunctional endothelial response during COVID-19 infection, due to direct COVID-19 infection of endothelial cells, aging, or chronic disease, turns into increased apoptosis and disruption of intercellular junctions. This, in turn, leads to increased permeability, leakage of fluid, leukocytes, and proteins. This hyperpermeability and leakage then interfere with oxygen exchange in the lungs and induce microcirculatory disorders in the heart [26].

(4) Damage Mediated by a Systemic Inflammatory Reaction and Cytokine Storm [20]. Research suggests that in COVID-19-infected patients, the systemic inflammatory reaction, immunologic derangement, and cytokine storm can lead to arrhythmia, thrombosis, coagulopathy, and other cardiovascular sequelae [23]. Guo et al. showed that rising troponin levels, indicating myocardial injury, in patients with COVID-19 correlated to rising C-reactive protein levels suggesting that the myocardial injury may be inflammation-mediated or related to an inflammatory mechanism. Inflammatory cytokines released due to COVID-19 infection may lead to tissue damage and dysfunction, reduce coronary blood flow and oxygen supply, and may lead to plaque destabilization and the formation of microthrombi [27]. Studies have shown that severe COVID-19 patients are exposed to high concentrations of cytokines [28]. Release of cytokines and damage-associated molecular patterns trigger endothelial activation leading to vasodilation and prothrombotic events [19, 29, 30]. These aspects of COVID-19 infection are driving factors of ARDS, coagulopathy, and COVID-19-related cardiovascular complications [31].

(5) Vessel Occlusion as a Result of Coagulopathy, Thrombosis, Embolus, Plaque Instability, or Plaque Rupture from the Systemic Inflammatory Response [20]. Occlusion leads to myocardial ischemia and infarction. COVID-19 patients are prone to venous thrombosis due to fever and diarrhea, hypotension due to dehydration, secondary infections, and prolonged bed rest [17]. Direct infection of endothelial cells increases cytokine production, enhances tissue factor expression, and increases NF-κB [32]. This, in turn, can trigger an inflammatory response and activation of the coagulation pathway, creating an ideal

International Journal of Vascular Medicine
environment for thrombotic events to occur [32, 33]. Platelets from critically ill COVID-19 patients showed upregulation of eIF4E, p38, and phosphorylation of ERK1/2, which indicates increased activation of the MAPK pathway. Increased MAPK signaling promotes thromboxane generation, a mechanism triggering platelet hyperactivity that may be present in COVID-19 patients [34]. Thrombotic events in patients with COVID-19 may be due to antiphospholipid antibodies. Still, it is difficult to differentiate the cause of a thrombotic event as it may coincide with other causes such as DIC, heparin-induced thrombocytopenia, and thrombotic microangiopathy [35] (6) Another Possible Cause Is Stress-Induced Cardiomyopathy and Cardiac Injury [20]. Increased cardiac workload, up to eight-fold, during viral infection, to compensate for the increased metabolic demands, compounded by the many effects of the infection on the lungs and breathing, considerably impairs cardiac function [36].

To summarize, direct injury, hypoxia, microvascular damage, and systemic inflammatory syndrome may all lead to inflammation of the heart, myocarditis, and acute cardiac injury.

2.2. Cardiac Complications. Myocarditis and acute cardiac injury further complicate the infection with the potential to lead to arrhythmia, heart failure, and cardiogenic shock [20]. Pertinent cardiac findings from several COVID-19 studies are presented in Table 1.

2.2.1. Myocarditis. Myocarditis has many different causes, including infection (viral, bacterial, etc.), autoimmune disease (SLE, etc.), and medications. Myocarditis can also be idiopathic. Inflammation seen in myocarditis can be focal or global, can lead to chamber dysfunction or nerosis, and has the potential to cause chronic cardiovascular complications [37].

The clinical presentation of COVID-19 is like the myocarditis of any etiology and includes fever, hypotension, dyspnea, chest pain, and arrhythmia. Viral myocarditis may also mimic myocardial infarction, acute coronary syndrome, or heart failure with nonspecific electrocardiographic changes (ST elevation, T-wave inversion, ST depression, and pathologic Q-waves), elevated enzymes, hemodynamic instability, tachycardia, displaced point of maximal impulse, or S3/S4 gallop. Myocarditis may also progress to heart block, arrhythmia, and impairment of left ventricular function [37–41].

Myocarditis, of any cause, is often preceded by flu-like and gastrointestinal symptoms. These are also some of the most common presenting symptoms of patients with COVID-19, making the diagnosis and management of the disease process tricky [42]. COVID-19-related myocarditis manifestation can range from mild symptoms to acute-onset heart failure. Patients who present with fulminant myocarditis often have a fever, sinus tachycardia, cold extremities, and low pulse pressure [43]. Recognition that viral myocarditis with the frequent rise in troponin is integral to the diagnostic and treatment approach considered in COVID-19-infected patients.

Fulminant myocarditis and heart failure have also occurred in COVID-19-infected patients [44]. Multiple case reports of fulminant myocarditis in COVID19 patients without underlying cardiovascular disease have been described [9, 19, 45]. While this type of injury could be due to direct damage to the heart by circulating virus, it is suspected to be mediated by immune system reaction and inflammation as most cases of fulminant myocarditis were sporadic and resolved after treatment [46]. An occurrence of acute myocarditis in an adolescent patient was reported. The patient had almost none of the typical signs and symptoms except fever, thus, indicating testing for COVID-19 in the pediatric age group with features suggestive of acute myocarditis [47].

A study of 1,216 patients with COVID-19 infection showed that 55% of patients that received an echocardiogram (due to suspected left or right heart failure, chest pain with ST-elevation, cardiac biomarker elevation, ventricular arrhythmia, suspected tamponade, or cardiogenic shock) had an abnormal echocardiogram. Left ventricular abnormalities were seen in 39%, and right ventricular abnormalities were seen in 33%. Evidence for myocardial infarction was seen in 3%, and evidence of myocarditis was seen in 3%. Of the 1216 patients, 901 (74%) patients did not have an underlying cardiac disease; still, 46% of them had abnormal echocardiograms, and 13% had severe disease. 25% of those without the preexisting cardiac disease had abnormal left ventricles, 33% had abnormal right ventricles [6].

2.2.2. Acute Coronary Syndrome (ACS). Increased risk for thrombotic events can lead to increased ACS risk in COVID-19 positive patients. Furthermore, upon onset of inflammation, ACS can be caused by plaque rupture due to macrophage activation, endothelial cell activation, smooth muscle cell activation, tissue factor expression, and further inflammation onset due to platelet activation [20]. Cases of both occluded and patent myocardial infarctions have been observed previously in the setting of viral illnesses [48–50].

Although the frequency remains unclear, myocardial injury with ST-segment elevation has been observed in COVID-19 patients. In a case series of 18 patients with COVID-19, 14 had focal ST-segment elevation, and four had diffuse ST-segment elevation. Ten patients had ST-segment elevation upon presentation. The other eight patients developed ST-segment elevation during hospitalization. Still, their treatment is unknown, and if it included azithromycin or hydroxychloroquine, it might have contributed to the development of rhythm abnormalities. Eight patients had a reduced left ventricular ejection fraction [8]. Several other case reports have demonstrated ST-segment elevation or Brugada pattern on electrocardiography [51–54]. The link between fever and Brugada pattern and cardiac arrest has been described extensively in the literature. Patients with Brugada pattern and COVID-19 should be monitored regardless of their respiratory conditions [55].
Table 1: Cardiac complications.

|                          | Eiros et al. [7] | Richardson et al. [113] | Bhatraju et al. [114] | Shi et al. [57] | Chen et al. [89] | Li et al. [25] | Wang et al. [115] | Liu et al. [11] | Arentz et al. [116] | Guan et al. [117] | Wang et al. [113] | Yang et al. [74] | Guo et al. [27] | Grimaud et al. [118] | Stefanini et al. [119] |
|--------------------------|------------------|-------------------------|-----------------------|----------------|----------------|----------------|----------------|----------------|-------------------|----------------|----------------|----------------|----------------|-------------------|------------------------|
| **N**                    | 139              | 5700                    | 24                    | 416            | 274            | 1527          | 339            | 137            | 150               | 1099           | 21             | 41             | 138             | 52                | 191               | 187                   | 20                | 28                |
| **Age (median)**         | 52               | 63                      | 64                    | 64             | 62             | n/a           | 71             | 57             | 47                | n/a            | 49             | 56             | 60              | 56                | 59                | 10                   | n/a               |
| **Cardiac symptoms**     |                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Chest pain               | 29%              |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Palpitations             | 32%              |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| **Clinical findings**    |                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| CMR abnormalities        | 75%              |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| ECG abnormalities        | 50%              |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Cardiomyopathy           |                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Myocarditis              | 37%              |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| **Myocardial infarction**|                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Cardiac injury biomarkers|                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Elevated troponin        |                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Arhythmia                |                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Heart failure            |                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Shock                    |                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Coagulopathy             |                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Medications              |                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Antibiotic use           | 41%              |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Antiviral use            | 12%              |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Mechanical ventilation   |                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| ICU                      | 23%              |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Non-ICU                  | 77%              |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Comorbidities            |                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Hypertension             | 12%              |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| CV disease               | 6%               |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Dyslipidemia             | 19%              |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Coronary artery disease  |                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| CHF                      |                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Cardiomyopathy           |                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
| Previous MI              |                  |                         |                       |                |                |               |                |                |                   |                |                |                |                 |                   |                     |                    |
|                | Eiros et al. [7] | Richardson et al. [113] | Bhatraju et al. [114] | Shi et al. [57] | Chen et al. [89] | Li et al. [25] | Wang et al. [115] | Liu et al. [11] | Ruan et al. [56] | Guan et al. [116] | Arentz et al. [75] | Huang et al. [117] | Wang et al. [13] | Yang et al. [110] | Zhou et al. [117] | Guo et al. [27] | Grimaud et al. [118] | Stefanini et al. [119] |
|----------------|-------------------|------------------------|----------------------|-----------------|------------------|-----------------|-------------------|-------------------|-----------------|-------------------|-------------------|-------------------|-----------------|-----------------|-------------------|-----------------|-------------------|-------------------|
| Survived       | —                 | 5147                   | 12                   | 359             | 161              | —               | 274               | 121               | 82              | 1084              | 10                | 35               | 132             | 20              | 137              | 144              | 20               | 17               |
| Death          | —                 | 553                    | 12                   | 57              | 113              | —               | 65                | 16                | 68              | 15                | 11                | 6                | 6               | 32              | 54                | 43               | 0                | 11               |
It is essential to note the overlapping disease course and symptomatology between ACS and COVID-19 [12]. The signs and symptoms of infection and cardiac damage can present similar to acute coronary syndrome; therefore, a high index of suspicion for differential diagnoses must be required by physicians, and alternative noninvasive diagnostic methods utilized [20].

2.2.3. Biomarkers of Myocardial Injury. The definition of myocardial or cardiac injury varies between studies, and no integrated definition is currently present. Varying definitions of myocardial injury are presented in Table 2. Elevated cardiac biomarker levels, myocardial inflammation, electrocardiographic abnormalities, and echocardiographic abnormalities are highly prevalent in patients with COVID-19. These signs are associated with a more severe disease course and a worse prognosis. Signs of myocardial injury have been seen in up to 30% of hospitalized COVID-19 patients [4, 27, 56, 57]. Evidence of myocardial injury is most often correlated to elevated troponin levels. Potential causes for elevated troponin in COVID-19 patients include myocarditis, cardiomyopathy, hypoxic injury, ischemic injury (increased oxygen demand due to fever or tachycardia, or decreased oxygen supply due to hypotension or hypoxemia), vascular or microvascular damage (due to increased reactive oxygen species, endothelin imbalance, or endothelial dysfunction), and systemic inflammation (cytokine storm).

The clinical value of troponin levels outside of acute coronary syndrome, myocardial infarction, and heart failure is difficult to quantify [27]. While abnormal troponin levels may lead to unnecessary use of resources and testing, all action must be taken to appropriately monitor and treat COVID-19-infected patients due to the similar presentation of ACS and COVID-19 infection and the potential for fatal outcomes.

Further research is needed to establish the clinical value of troponin levels in COVID-19-infected patients. Elevated troponin levels were associated with elevated levels of CRP and NT-proBNP, linking myocardial injury to the severity of inflammation and ventricular dysfunction [27].

2.2.4. Arrhythmia. Arrhythmias represent one of the complications of COVID-19 infection, demonstrated in 16.7% of patients with an increased prevalence of 44.4% in patients admitted to the ICU [4, 58]. Arrhythmia was demonstrated in another study in 16.7% of hospitalized COVID-19 patients [13]. There appear to be more possible mechanisms causing arrhythmia in COVID-19 patients than other cardiac complications, possibly explaining its high prevalence. Arrhythmia could result from myocarditis, myocardial ischemia, infection-induced hypoxia, fever, metabolic disarray, hormonal dysregulation, medication, or inflammation.

Myocarditis-induced arrhythmias have been seen in COVID-19 positive patients in an acute setting or chronic myocarditis [43]. Electrolyte abnormalities, in particular, hypokalemia, which can occur in any systemic illness, may also be of particular concern in causing arrhythmia in COVID-19-infected patients due to the virus’ interaction with the renin-angiotensin-aldosterone system [59]. Myocarditis or myocardial inflammation could result in sinus node dysfunction and, ultimately, arrhythmia in COVID-19 patients [60, 61].

Palpitations were one of the most common presenting symptoms in 7.3% of patients in a cohort of 137 COVID-19 patients [11]. More serious arrhythmia complications shown to arise in COVID-19 infection include ventricular tachycardia, atrial fibrillation, ventricular fibrillation, atrioventricular block, and cardiogenic shock [4, 58, 62]. Patients diagnosed with COVID-19 infection that have elevated cardiac biomarkers may develop new-onset arrhythmia. New-onset arrhythmia in the setting of elevated cardiac biomarkers can indicate myocarditis and should raise suspicion for underlying myocarditis. Primary care physicians must include this in their treatment plan and provide adequate monitoring and follow-up [4].

The risk of arrhythmia could also be associated with the usage of early COVID-19 treatments such as azithromycin and hydroxychloroquine. The use of hydroxychloroquine and azithromycin has independently been shown to cause arrhythmia [63, 64]. While they were used in COVID-19 patients, no studies were found separating COVID-19 patients experiencing arrhythmia into groups receiving the drug(s) and not receiving the drug(s). This makes it even more challenging to discern a cause of arrhythmia and the true prevalence of arrhythmia in patients with COVID-19.

Table 2: Definition and incidence of cardiac injury from COVID-19 studies.

| Study          | Patients (N) | Cardiac injury definition          | Incidence of cardiac injury in COVID-19 infection (N (%) |
|----------------|--------------|------------------------------------|--------------------------------------------------------|
| Guo et al. [27] | 187          | Elevated troponin-T                | 52 (27.8%)                                             |
|                |              | Elevated hs-troponin-I             |                                                       |
| Huang et al. [117] | 41          | ECG                                | 5 (12%)                                                |
|                |              | Echo                               |                                                       |
| Wang et al. [13] | 138         | ECG                                | 10 (7.2%)                                              |
|                |              | Echo                               |                                                       |
| Yang et al. [120] | 52         | Elevated hs-troponin-I             | 12 (23%)                                               |
|                |              | Elevated troponin-I                |                                                       |
| Zhou et al. [74] | 191         | ECG                                | 33 (17%)                                               |
|                |              | Echo                               |                                                       |
infection not taking hydroxychloroquine or azithromycin [11–13, 65]. Another evidence showed that many patients might have higher QT values even before starting the drugs potentially causing further QT prolongation [66]. In patients grouped under “Out of hospital arrests” during the COVID-19 pandemic, a study on post-ROSC (return of spontaneous circulation) showed prolonged QTc values in 12 out of 27 patients [67]. The incidence of arrhythmia needs to be further evaluated in future studies in COVID-19 patients not given azithromycin or hydroxychloroquine, as the exact contribution of COVID-19 infection to arrhythmia development is unknown. Hence, physicians must keep the risk of arrhythmia and myocarditis in mind when treating and evaluating COVID-19 patients.

2.2.5. Out of Hospital Cardiac Arrest (OHCA). A higher incidence of out-of-hospital cardiac arrest has been noted in patients suspected of or with a confirmed diagnosis of COVID-19 [68] [67]. Even in patients on whom emergency personnel attempted resuscitation, OHSA occurred at 14.9% points more in 2020 as compared to 2019 [69]. Another study observed a lower attitude of laypeople in initiating cardiopulmonary resuscitation during the COVID-19 outbreak compared to 2019. The study also noted that a confirmed or suspected COVID-19 infection did not influence the resuscitative attempts by BLS and ALS staff [70]. A doubling of the incidence of OHCA and a simultaneous reduction in survival rate that was noticed during the COVID-19 pandemic was also noted in Paris. The rise was partly attributed to COVID-19 infection and indirectly related to lockdown and health care services-related adjustments [71]. When the number of COVID-19 cases peaked in New York City, a three-fold higher number of OHCA underwent resuscitation compared to the same period in 2019 and most were older, more likely to have specific comorbidities [72]. A study across a longer time period confirmed that the OHCA trend paralleled the ascending and descending phases of the COVID-19 pandemic [73].

2.2.6. Heart Failure. Heart failure has been shown to occur in up to 23% of infected patients. They seem to occur secondary to exacerbation of left ventricular dysfunction, myocarditis, acute coronary syndrome, arrhythmia, pulmonary hypertension, ARDS, or cardiomyopathy [12, 74]. The incidence of cardiomyopathy in critically ill ICU patients has yet to be evaluated on a large scale but has been shown to develop in up to 33% of patients [75]. A small case series of COVID-19 patients with acute cor pulmonale showed profound hemodynamic instability and cardiac arrest with acute right ventricular failure [76].

2.2.7. Children and Multisystem Inflammatory Syndrome. The pediatric population appears to have a milder clinical course but may still show some cardiac complications such as arrhythmia and must be monitored [77]. A systemic inflammation syndrome, like Kawasaki disease, has been shown in children as well. A case report of a pediatric patient diagnosed with COVID19, presenting with Kawasaki-like disease, showed arrhythmia, electrocardiographic abnormalities, elevated biomarkers, left ventricular systolic dysfunction, pericardial effusion, delayed capillary refill, and gallop on auscultation [78]. Kawasaki disease is associated with left ventricular systolic dysfunction in 20% of patients, coronary artery dilation in 29%, and mitral regurgitation in 27%, suggesting shared mechanisms between Kawasaki disease, cardiac complications and abnormalities, and myocarditis [79]. Despite having a milder clinical course, children should be monitored for cardiac complications and, upon presenting with any Kawasaki-like disease, should be tested for COVID-19.

2.3. Vascular Complications. A wide range of vascular complications has been recognized in patients affected with COVID-19 that include venous and arterial thrombosis, neurological ischemic events, and coagulopathy as summarized in Table 3.

2.3.1. Venous Thrombotic Events (VTE). In a recent study, 184 COVID-19 positive patients in the ICU were evaluated for thrombotic events. All the patients received standard doses of thromboprophylaxis following hospital protocol upon arrival [80]. The patients were in the hospital for a median duration of 7 days: 27% of the patients had confirmed VTE by CTAP or ultrasonography and 3.7% had arterial thrombotic events [80]. Approximately 31% of patients with COVID-19 in the ICU had thrombotic complications despite thromboprophylaxis [80]. These patients also exhibited prolonged PT (prothrombin time) and aPTT (activated partial thromboplastin time) time [80].

2.3.2. Concomitant Venous and Arterial Thrombotic Events. In a case study, a COVID-19 positive patient was observed to have a severe case of venous thrombosis and arteriosclerosis obliterans of the lower extremities. The patient had a past medical history of uncontrolled type 2 diabetes. Upon arrival to the hospital, lab report showed marked C-reactive protein increase and elevated D-dimer level of over eight ug/mL with a normal PT and aPTT. Vascular ultrasound found DVT in the left lower extremity (LLE) and dorsalis pedis artery occlusion in the LLE on arrival. Anticoagulation and other supportive therapy were given, and after three days, vascular ultrasound confirmed bilateral lower extremity thrombosis with arterial tibialis anterior occlusion and dorsalis pedis artery occlusion on both lower extremities. This patient specifically had many risks and predispositions for DVT, however, it should be anticipated that an infection like COVID-19 could encourage an even greater hypercoagulable environment as seen with this patient who after three days developed many more clots [18].

Three of four COVID-19 patients in another case series had dermal arterial thrombosis suggestive of antiphospholipid syndrome, one also developed venous thrombosis, and all four patients had elevated D-dimer [81]. Another case series reported arterial thrombosis in three patients. A patient, one-week post-COVID-19-recovery, presented with thrombotic occlusion of all tibial arteries on the right leg, an aortic thrombus in the visceral aorta, and thrombotic occlusion of the left popliteal artery. A patient with no...
| Study                  | Total population | Hearts studied | Mean/range age (years) | Cardiac comorbidities | Mean time to death | Cardiac enlargement | Other findings                          | Cardiac interstitial fibrosis | Epicardial mononuclear infiltrate | Myocardial infarction | Elevated D-dimer | Neurological vascular lesions | Venous thromboembolism | Other |
|-----------------------|------------------|----------------|------------------------|-----------------------|--------------------|---------------------|----------------------|-------------------------------------|-------------------------------|----------------------|-------------------------------|------------------------|--------|
| Bryce et al. [93]     | 67               | 25             | 69 (range 34-94)       | Hypertension (62.7%), coronary artery disease (31.3%), heart failure (14.9%), atrial fibrillation (13.4%) | 9.5 days (range 0-61) from admission | Left ventricular hypertrophy (100%) | Myocyte hypertrophy and interstitial fibrosis | 100%                               | 60%                           | —                           | 80.6%                  | Cerebral infarct (30%)            | 6%                     | Intravascular fibrin thrombi (25%), CD61 platelet aggregates or thrombi (31%), large pulmonary emboli (6%) |
| Fox et al. [95]       | 10 (African American) | 9             | Range 44-78            | Hypertension (70%), atrial fibrillation (10%), heart failure (10%) | 8.2 days (range 0-25) from admission; 116.6 days from symptom onset | Right ventricular dilation | Scattered myocyte necrosis; no significant lymphocytic infiltration | —                                  | —                             | 90%                          | —                      | —                               | —                      | Small, firm thrombi in peripheral parenchyma (100%) |
| Tian et al. [121]     | 4                | 2              | Range 59-81            | Hypertension (25%)    | 15.52 days from disease onset | —                   | —                                | 100%                               | —                             | —                             | —                      | —                               | —                      | —                               |
| Rapkiewicz et al. [100] | 7                | 4              | Range 44-65            | Hypertension (85%), coronary artery disease (14%) | 12.9 days (range 3-25) from symptom onset; mean 4.4 days from admission | —                   | Megakaryocytes with fibrin microthrombi in cardiac microvasculature (7/7) | —                                  | 25%                           | 25%                          | 100%                  | —                               | —                      | Pulmonary arterial thrombi (29%), CD61 platelet aggregates or thrombi (100%) |
| Bradley et al. [96]   | 12               | 12             | 70.4                   | —                     | —                   | —                   | Myocyte hypertrophy (12/12) | 85%                               | —                             | —                             | —                             | —                      | Subsegmental pulmonary emboli (17%) |
| Giacca et al. [102]   | 41               | 30             | Male -77; female -84   | Cardiomyopathy (11.5%), arrhythmia (1.25%), cardiac insufficiency (38.75%), atrial fibrillation (18.75%), hypertension (31.23%) | —                   | —                   | —                                | —                                  | Cardiomyocyte damage suggestive of hypoxic injury (54%) | 24%                          | —                      | —                               | —                      | Pulmonary thrombosis (77%) |
| Edler et al. [97]     | 80               | 80             | Mean 79.2              | —                     | —                   | —                   | —                                | —                                  | —                             | —                             | —                      | —                      | —                      | 40% Pulmonary embolism (21%) |

Table 3: Vascular complications and pathology.
| Study          | Total population | Hearts studied | Mean/range age (years) | Cardiac comorbidities                                                                 | Mean time to death | Cardiac enlargement          | Other findings                                                                 | Cardiac interstitial fibrosis | Epicardial mononuclear infiltrate | Myocardial infarction | Elevated D-dimer | Neurological vascular lesions | Venous thromboembolism | Other                      |
|----------------|------------------|----------------|------------------------|---------------------------------------------------------------------------------------|--------------------|-------------------------------|--------------------------------------------------------------------------------|-----------------------------|--------------------------|------------------------|---------------------|--------------------------|--------------------------|--------------------------|
| Lax et al. [94] | 11               | 11             | Mean 80.5 (range 66-91)| Hypertension (81.8%), coronary artery disease (27.27%)                                | 8.55 days (range 4-18) from symptom onset | Biventricular hypertrophy (100%), biventricular dilatation (91%) | —                                                                              | 90.90%                      | —                        | —                      | 86%                 | —                        | —                        | Pulmonary arterial thrombosis |
| Wichmann et al. [98] | 12           | 12             | Mean 73 (range 52-87) | Coronary/ischemic heart disease (50%)                                                   | —                  | Biventricular hypertrophy (25%) | —                                                                              | —                           | —                        | 50%                    | 71%                 | —                        | 58%                      | Pulmonary embolism          |
atherosclerotic or thromboembolism risk had an occlusive thrombus at the aortic bifurcation with occlusion of the right common iliac artery and stenosis of the left common iliac artery. Another patient developed a stroke in the territory of the left middle cerebral artery [82].

Additionally, certain types of rashes in COVID-19 patients may be an early clinical sign of an underlying thrombotic or hypercoagulable state [81, 83]. Primary care physicians caring for COVID-19 patients must be aware of hallmark manifestations of cutaneous thrombosis including livedoid and purpuric rashes and necrotic eruptions, all associated with elevated D-dimer levels [81].

2.3.3. Stroke. Mao et al. (2020) studied 214 patients that tested positive for COVID-19, and of these patients, 36.4% were found to have neurologic symptoms. 41.1% of the patients in this study were severely infected. They had a higher prevalence of nervous system events such as ischemic stroke and cerebral hemorrhage, as well as symptoms of impaired consciousness. They also had high white cell count, high neutrophil count, low lymphocyte counts, and elevated C-reactive protein (CRP) levels when compared to patients with nonsevere infection [84]. Through this study, the importance of screening severe patients that are older, presenting with comorbidities and fewer typical symptoms of COVID-19, for the potential of stroke or other neurologic symptoms is evident.

In a case study in Wuhan, China, three critically ill patients that tested positive for COVID-19 were observed to have coagulopathies. Imaging showed that all three COVID-19 positive patients developed multiple cerebral infarcts. Patient 3 developed a thrombotic event 18 days from disease onset, while patients 1 and 2 developed thrombotic events 18 and 33 days after disease onset, respectively. All the patients showed leukocytosis, thrombocytopenia, elevated fibrinogen, elevated d dimer, and presence of antiphospholipid IgA and IgG antibodies [85].

A retrospective study looked at four COVID-19 positive patients that presented with acute stroke. All patients had hypertension. This may suggest the importance of considering comorbidities, especially hypertension, when analyzing patients for risk of mortality due to COVID-19 presenting with stroke. Two of the patients presented with left shift $h$, while the other two had an elevated cardiac troponin T and D-dimer. IL-6 was only taken in patient 4, and it was elevated, C-reactive protein was tested in patient 1, 3, and 4 and was significantly elevated in all [29]. These results are consistent with other case studies discussed in which patients presented with coagulopathies.

2.4. Coagulopathy. During the outbreak of COVID-19 in Wuhan, China, abnormal coagulation patterns were recorded by some investigators. One case study investigated 183 patients who were confirmed COVID-19 positive [16]. Of these patients, 71.4% of nonsurvivors and 0.6% of survivors met the criteria of coagulopathy during their hospital stay [16]. An 11.5% mortality was reported in this study. These patients were revealed to have significantly higher D-dimer and fibrin degradation product levels, prolonged PT, and aPTT time compared to those patients that survived [16]. Although the laboratory findings were consistent with the classic presentation of disseminated intravascular coagulation (DIC), COVID-19 patients generally tend to have thrombotic events rather than the bleeding that is often seen in DIC. However, studies have shown the difference between the presentation of COVID-19-associated coagulopathy (CAC) and classic DIC [86].

COVID-19 patients presenting with vasculopathies often had abnormal PT/aPTT, D-dimer, and platelet counts [15, 16, 18, 19, 29, 80, 84, 85, 87, 88]. Ninety-nine patients with COVID-19 were used in a retrospective study to look at clinical outcomes with symptoms and lab values documented [89]. The aPTT was found to be decreased in 16% of patients, while the PT was found to be decreased in 30% of patients [89]. A much smaller percentage of patients have an increase in PT or aPTT [89]. In CAC, PT and aPTT may be prolonged or normal, while in DIC, they are both elevated. Prolonged aPTT/PT levels may also be due to administration of LMWH in the hospital, and aPTT prolongation may be due to the presence of antiphospholipid antibodies [90]. In DIC, fibrinogen levels may be normal to low due to fibrinolysis suppression from the overproduction of plasminogen activator inhibitor 1 (PAI-1), while in CAC, fibrinogen levels are elevated [86]. Platelet counts may be high or low in CAC, while in DIC, they are consistently low [86]. Low platelet counts can be indicative of platelets forming aggregates that may result in a thrombotic event [87]. Antiphospholipid antibodies are present in lab testing of COVID-19 patients that present with thrombotic events [85]. Complement is activated, and antiphospholipid antibodies are present in CAC, while both are negative in DIC [86]. In both DIC and CAC, the primary cause and target of coagulopathy are the macrophage and endothelial cells resulting in microthrombosis, with additional venous thrombosis seen in CAC [86]. Endothelial dysfunction and direct endothelial infection can cause a dysfunctional endothelial response during COVID-19 infection. This further contributes to the pathogenesis of thrombosis, coagulation disorders, and myocardial injury in COVID-19 patients [26]. Elevated D-dimer and increased inflammatory cytokines IL-1β and IL-6 are also seen in both [86]. D-dimer elevation may be due to the vascular disease state created in some COVID-19 patients along with potential multisystem organ involvement, low-grade inflammation, and hypercoagulability [30].

Elevated C-reactive protein was also found in some patients presenting with COVID-19 [18, 29, 84, 89]. C-reactive protein typically increases significantly with inflammation [91]. Inflammation plays a significant role in the pathogenesis of clot formation. C-reactive protein has also been found to promote platelet adhesion to the endothelial cell lining, promoting thrombosis [92]. Studies noted this elevated finding, however, did not discuss it in too much detail. Further studies on the correlation of C-reactive protein and thrombotic events in COVID-19 patients would provide a better sense of the importance of using this lab test in the care of COVID-19 patients.
2.5. Pathology. Many studies have reported cardiac autopsy findings in COVID-19 patients (Table 3). The gross findings were reported to be cardiomegaly variably involving the chambers such as global hypertrophy, biventricular hypertrophy or left ventricular hypertrophy, and right ventricular dilatation [93–95]. The histopathological examination revealed myocyte hypertrophy, areas of infarction, lymphocytic infiltration within the myocardium with or without necrosis, epicardial mononuclear infiltrates, and lymphocytic endothelitis [95–99]. A rare finding of an increased number of megakaryocytes in cardiac tissue with fibrin microthrombi was also noted [100].

The presence of SARS CoV-2 RNA was found in the autopsied hearts [96, 98, 101]. Another report showed isolated cells of heart tissue testing positive for viral RNA, not accompanied by viral replication, infection, or inflammation [102]. Endomyocardial biopsy (EMB) in a COVID-19-infected patient showed low-grade myocardial inflammation and viral particles in the myocardium, suggesting either a viremic phase or, alternatively, infected macrophage migration from the lung [103]. Another study showed myocardial inflammation with elevated lymphocytes and macrophages in the absence of tissue necrosis [104]. EMB serves in an accurate diagnosis and provides tissues for the development of specific biomarkers for SARS-CoV-2 myocarditis. However, its use is limited due to contagious spread risk [43].

2.6. Further Implications of COVID-19 on Cardiovascular System

2.6.1. Cardiovascular Symptoms as the Primary Clinical Presentation. The National Health Commission of China (NHC) has shown some patients with later confirmed COVID-19 first presented to the doctor because of cardiovascular symptoms such as heart palpitations and chest tightness [3, 11]. A case report of a healthy patient testing positive for COVID-19 reported findings of myopericarditis accompanied by systolic dysfunction. Additionally, NT-proBNP and troponin T levels were elevated, ST elevation was seen on electrocardiography, and thickened walls and diffuse edema were detected on cardiac magnetic resonance imaging. The patient did not show any respiratory involvement during the clinical course. These findings could indicate eventual heart failure onset [105]. A patient with exertional angina presented without fever or respiratory symptoms showed elevated cardiac biomarkers and tested positive for COVID-19 [106]. Another case report was about a patient with persistent chest pressure for two days. The patient denied cough, fever, and dyspnea. Initial ECG showed ST-elevation. The predominant symptoms the patient presented with were cardiac in nature, and there were no signs of infection; however, the patient tested positive for COVID-19 [107].

2.6.2. Cardiovascular Complications in Patients without Underlying Cardiac Disease. The NHC showed that 11.8% of patients without the underlying cardiovascular disease had substantial heart damage with elevated troponin levels and cardiac arrest [3, 11]. Of the 1216 patients in an echocardiography study of COVID-19 patients, 901 (74%) patients did not have underlying cardiac disease, yet still, 46% of them had abnormal echocardiograms, and 13% had severe disease. 25% of those without preexisting cardiac disease had abnormal left ventricles, and 33% had abnormal right ventricles [6]. Multiple case reports of fulminant myocarditis, cardiac hypertrophy, electrocardiographic abnormalities, echocardiographic abnormalities, elevated biomarkers, and shock have also all been described [9, 45]. A patient without any past medical history was detailed, showcasing the development of atrial fibrillation days after the onset of COVID-19 infection [62]. Another patient with COVID-19 presented with T-wave inversion, elevated troponin and natriuretic peptides, and echocardiographic signs of left ventricular dysfunction and was confirmed to have myocarditis. He had no history of cardiovascular disease, coronary artery disease, heart failure, lung disease, cancer, hypertension, or smoking [104].

Evaluation of cardiac manifestations in all COVID-19 confirmed or suspected cases is recommended to include but not limited to cardiac symptoms, chest X-ray or CT, unstable vital signs, cardiac biomarkers (ULN of CK-MB, Tn-I, Tn-T), electrocardiography, and echocardiography. It has been shown that cardiovascular complications in COVID-19 infection indicate a worse prognosis [4]. Early investigation, monitoring, and treatment are warranted. Physician recognition that viral myocarditis and notably COVID-19 simulating a myocardial infarction presentation with the frequent rise in troponin is integral to the diagnostic and treatment approach considered in COVID-19-infected patients [12]. Further research is needed to determine the time of onset of cardiac complications to make a recommendation on when this monitoring should be started.

2.6.3. Does the Risk of Cardiovascular Disease Persist after COVID-19 Infection? A cohort of 100 COVID-19-recovered patients showed independent of preexisting conditions, CMR evidence of cardiac involvement in 78%, and ongoing myocardial inflammation in 60% of patients 2 to 3 months after diagnosis [108]. Another study showed that in patients with no comorbidities, the death rate was 61.5% with elevated hs-Tnl and cardiac involvement [69]. Abnormalities included raised myocardial native T1 and native T2, myocardial late gadolinium enhancement (LGE) indicative of regional scarring, pericardial enhancement, elevated troponin, and decreased left ventricular ejection fraction [108]. This study suggests long-lasting cardiac involvement and exposes the need for ongoing investigation and monitoring of long-term cardiovascular complications from COVID-19.

While often bacterial, an increased risk of cardiovascular disease and complications has been linked to pneumonia in a 10-year follow-up study [109]. It is likely that COVID-19 as a primarily respiratory illness, whether pneumonia-like or respiratory distress, will cause similar adverse outcomes. A research suggested that COVID-19-recovered patients will continue to have subclinical or apparent clinical cardiovascular abnormalities, and that those with recovered cardiac function may continue to be at higher risk of developing
cardiomyopathy and arrhythmia. The authors suggested developing cardiac screening tools for COVID-19-recovered patients now so that future complications can be caught and managed early. Myocardial injury, microinfarction, and fibrosis can lead to long-term cardiovascular sequelae postinfection such as cardiomyopathy, systolic and diastolic dysfunction, PVCs and VT, and atrial fibrillation [110]. The concern of myocardial inflammation led to investigating the use of cardiac magnetic resonance (CMR) imaging in competitive athletes recovered from COVID-19 [111]. CMR may allow risk stratification before the post-COVID patients can resume their athletic physical activity [111]. It is too early to know if long-term heart damage will be seen in these patients. Follow-up studies such as CISCO-19 [112] and other long-term screening measures are needed. Long-term follow-up studies of these diseases and their association with cardiovascular disease development are scarce. Follow-up studies of COVID-19 survivors are needed.

3. Conclusion

Acute cardiac injury is a common cardiovascular complication of COVID-19, and it occurs from direct myocardial injury, inflammation, myocardial oxygen supply, and demand mismatch, acute coronary events, and can be iatrogenic or from other unknown causes. Acute coronary events do not appear to be well documented but could result from plaque rupture or aggravation of the preexisting coronary disease. Heart failure can also result from myocardial injury or dysfunction or increased metabolic demand due to systemic disease, causing an acute decompensation of preexisting heart failure. Arrhythmia seems to occur in both mild and severe cases. However, little is known about the clinical value of these complications and manifestations of heart disease in COVID-19. Biomarker elevation, cardiac injury, and other cardiac sequelae may reflect the systemic disease and clinical course of COVID-19 infection.

Prolonged PT and aPTT, elevated d-dimer levels, and increased fibrin degradation levels are linked to a higher risk of mortality in COVID-19 patients. The mentioned lab values, excluding the PT/aPTT, signify a hypercoagulable state in a patient, which indicates potential thromboembolism. VTE has frequently been reported, and, upon presentation, patients with suspected and confirmed COVID-19 infection should be assessed for VTE risk. In treating patients with COVID-19, antiplatelet and anticoagulation therapies should be considered. Continued monitoring for signs of cardiac damage and coagulation (D-dimer) can help predict and potentially prevent COVID-19 complications.

The cardiovascular system is involved early in the disease course reflected in the release of prognostic and highly sensitive troponin and natriuretic peptides. Still, the actual time of onset of cardiovascular complications and symptoms has not been formally evaluated, leaving room for improvement in future research. Developing a cardiovascular screening protocol for COVID-19-recovered patients is crucial for monitoring the patients on a long-term basis by the primary care physician.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Aaron Schmid, Marija Petrovic, Kavya Akella, and Anisha Pareddy conceived the idea of the review; Aaron Schmid initiated the design of creating the manuscript; all the authors were involved in literature search and review, writing, revision, and final approval of the manuscript.

Acknowledgments

The authors would like to acknowledge Daniel Gelfman, MD, for his time in reviewing and providing thoughtful guidance.

References

[1] WHO, Q &A on coronaviruses (COVID-19), World Health Organization, 2020.
[2] M. Madjid, P. Safavi-Naeini, S. D. Solomon, and O. Vardeny, “Potential effects of coronaviruses on the cardiovascular system: a review,” JAMA Cardiology, vol. 5, no. 7, pp. 831–840, 2020.
[3] Y. Y. Zheng, Y. T. Ma, J. Y. Zhang, and X. Xie, “COVID-19 and the cardiovascular system,” Nature Reviews. Cardiology, vol. 17, no. 5, pp. 259–260, 2020.
[4] E. Driggin, M. V. Madhavan, B. Bikdeli et al., “Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic,” Journal of the American College of Cardiology, vol. 75, no. 18, pp. 2352–2371, 2020.
[5] G. D. Batty and M. Hamer, “Vascular risk factors, Framingham risk score, and COVID-19: community-based cohort study,” Cardiovascular Research, vol. 116, no. 10, pp. 1664–1665, 2020.
[6] M. R. Dweck, A. Bularga, R. T. Hahn et al., “Global evaluation of echocardiography in patients with COVID-19,” European Heart Journal Cardiovascular Imaging, vol. 21, no. 9, pp. 949–958, 2020.
[7] R. Eiros, M. Barreiro-Perez, A. Martin-Garcia et al., “Pericarditis and myocarditis long after SARS-CoV-2 infection: a cross-sectional descriptive study in health-care workers,” medRxiv, 2020.
[8] S. Bangalore, A. Sharma, A. Slotwiner et al., “ST-segment elevation in patients with covid-19 – a case series,” The New England Journal of Medicine, vol. 382, no. 25, pp. 2478–2480, 2020.
[9] H. Hu, F. Ma, X. Wei, and Y. Fang, “Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin,” European Heart Journal, vol. 42, no. 2, p. 206, 2021.
[10] P. Meyer, S. Degrauwe, C. Van Delden, J. R. Ghadri, and C. Templin, “Typical takotsubo syndrome triggered by SARS-CoV-2 infection,” European Heart Journal, vol. 41, no. 19, p. 1860, 2020.
[11] K. Liu, Y. Y. Fang, Y. Deng et al., “Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province,” Chinese Medical Journal, vol. 133, no. 9, pp. 1025–1031, 2020.
[12] K. Mahajan and S. Chandra, "Cardiovascular comorbidities and complications associated with coronavirus disease 2019," *Medical Journal, Armed Forces India*, vol. 76, no. 3, pp. 253–260, 2020.

[13] D. Wang, B. Hu, C. Hu et al., "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China," *JAMA*, vol. 323, no. 11, pp. 1061–1069, 2020.

[14] P. K. Vlachakis, A. Tentolouris, D. Tousoulis, and N. Tentolouris, "Current data on the cardiovascular effects of COVID-19," *Hellenic Journal of Cardiology*, vol. 61, no. 1, pp. 46–48, 2020.

[15] J. Sung and S. Anjum, "Coronavirus disease 2019 (COVID-19) infection associated with antiphospholipid antibodies and four-extremity deep vein thrombosis in a previously healthy female," *Cureus*, vol. 12, article e8408, 2020.

[16] N. Tang, D. Li, X. Wang, and Z. Sun, "Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia," *Journal of Thrombosis and Haemostasis*, vol. 18, no. 4, pp. 844–847, 2020.

[17] Z. Zhai, C. Li, Y. Chen et al., "Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines," *Thrombosis and Haemostasis*, vol. 120, no. 6, pp. 937–948, 2020.

[18] B. Zhou, J. She, Y. Wang, and X. Ma, "Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report," *Journal of Thrombosis and Thrombolysis*, vol. 50, no. 1, pp. 229–232, 2020.

[19] B. Bikdeli, M. V. Madhavan, D. Jimenez et al., "COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review," *Journal of the American College of Cardiology*, vol. 75, no. 23, pp. 2950–2973, 2020.

[20] I. C. Kim, H. A. Kim, J. S. Park, and C. W. Nam, "Updates of cardiovascular manifestations in COVID-19: Korean experience to broaden worldwide perspectives," *Korean Circulation Journal*, vol. 50, no. 7, pp. 543–554, 2020.

[21] H. Liu, S. Gai, X. Wang et al., "Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart," *Cardiovascular Research*, vol. 116, no. 10, pp. 1733–1741, 2020.

[22] G. Tersalvi, M. Vicenzi, D. Calabretta, I. Biasco, G. Pedrazzini, and D. Winterton, "Elevated troponin in patients with coronavirus disease 2019: possible mechanisms," *Journal of Cardiac Failure*, vol. 26, no. 6, pp. 470–475, 2020.

[23] A. S. Larson, L. Savastano, R. Kadirvel, D. F. Kallmes, A. E. Hassan, and W. Brinjikji, "Coronavirus disease 2019 and the cerebrovascular-cardiovascular systems: what do we know so far?," *Journal of the American Heart Association*, vol. 9, no. 13, article e016793, 2020.

[24] W. Tan and J. Aboulhosn, "The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease," *International Journal of Cardiology*, vol. 309, pp. 70–77, 2020.

[25] G. Li, R. Hu, and X. Gu, "A close-up on COVID-19 and cardiovascular diseases," *Nutrition, Metabolism, and Cardiovascular Diseases*, vol. 30, no. 7, pp. 1057–1060, 2020.

[26] J. F. Bermejo-Martin, R. Almansa, A. Torres, M. Gonzalez-Rivera, and D. J. Kelvin, "COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction," *Cardiovascular Research*, vol. 116, no. 10, pp. e132–e133, 2020.

[27] T. Guo, Y. Fan, M. Chen et al., "Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)," *JAMA Cardiology*, vol. 5, no. 7, pp. 811–818, 2020.

[28] S. Mohammadi, M. Abouzaripour, N. Hesam Shariati, and M. B. Hesam Shariati, "Ovarian vein thrombosis after coronavirus disease (COVID-19) infection in a pregnant woman: case report," *Journal of Thrombosis and Thrombolysis*, vol. 50, no. 3, pp. 604–607, 2020.

[29] A. Avula, K. Nalleballe, N. Narula et al., "COVID-19 presenting as stroke," *Brain, Behavior, and Immunity*, vol. 87, pp. 115–119, 2020.

[30] D. E. Leisman, C. S. Deutschman, and M. Legrand, "Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation," *Intensive Care Medicine*, vol. 46, no. 6, pp. 1105–1108, 2020.

[31] P. C. Evans, G. E. Rainger, J. C. Mason et al., "Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science," *Cardiovascular Research*, vol. 116, no. 14, pp. 2177–2184, 2020.

[32] S. Subramaniam and I. Scharrer, "Procoagulant activity during viral infections," *Frontiers in Bioscience*, vol. 23, no. 3, pp. 1060–1081, 2018.

[33] J. C. Kwong, K. L. Schwartz, and M. A. Campitelli, "Acute myocardial infarction after laboratory-confirmed influenza infection," *The New England Journal of Medicine*, vol. 378, no. 26, pp. 2540–2541, 2018.

[34] B. K. Manne, F. Denorme, E. A. Middleton et al., "Platelet gene expression and function in patients with COVID-19," *Blood*, vol. 136, no. 11, pp. 1317–1329, 2020.

[35] Y. Zuo, S. K.Estes, R. A. Ali et al., "Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19," *Science Translational Medicine*, vol. 12, no. 570, article eaab3876, 2020.

[36] R. Adao and T. J. Guzik, "Inside the heart of COVID-19," *Cardiovascular Research*, vol. 116, no. 6, pp. e59–e61, 2020.

[37] M. Esfandiarei and B. M. McManus, "Molecular biology and pathogenesis of viral myocarditis," *Annual Review of Pathology*, vol. 3, no. 1, pp. 127–155, 2008.

[38] G. W. Dec Jr., H. Waldman, J. Southern, J. T. Fallon, A. M. Hutter Jr., and I. Palacios, "Viral myocarditis mimicking acute myocardial infarction," *Journal of the American College of Cardiology*, vol. 20, no. 1, pp. 85–89, 1992.

[39] Group JCSJW, "Guidelines for diagnosis and treatment of myocarditis (JCS 2009)," *Circulation Journal*, vol. 75, no. 3, pp. 734–743, 2011.

[40] G. Hufnagel, S. Pankuweit, A. Richter, U. Schonian, and B. Maisch, "The pathogenesis of viral myocarditis," *Annual Review of Pathology*, vol. 11, no. 1, pp. 1009, 2015.
[43] B. Siripanthong, S. Nazarian, D. Muser et al., “Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management,” *Heart Rhythm*, vol. 17, no. 9, pp. 1463–1471, 2020.

[44] R. O. Bonow, G. C. Fonarow, P. T. O’Gara, and C. W. Yancy, “Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality,” *JAMA Cardiology*, vol. 5, no. 7, pp. 751–753, 2020.

[45] J. H. Zeng, Y. X. Liu, J. Yuan et al., “COVID-19 complicated with fulminant myocarditis: a case report and insights,” *Infection*, vol. 48, no. 5, pp. 773–777, 2020.

[46] X. Wei, Y. Fang, and H. Hu, “Immune-mediated mechanism in coronavirus fulminant myocarditis,” *European Heart Journal*, vol. 41, no. 19, article 1855, 2020.

[47] M. Gneccci, F. Moretti, E. M. Bassi et al., “Myocarditis in a 16-year-old boy positive for SARS-CoV-2,” *The Lancet*, vol. 395, no. 10242, article e116, 2020.

[48] G. Cuervo, D. Viasus, and J. Carratala, “Acute myocardial infarction after laboratory-confirmed influenza infection,” *The New England Journal of Medicine*, vol. 378, p. 2540, 2018.

[49] G. Lippi, C. J. Lavié, and F. Sanchis-Gomar, “Cardiac tropinin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis,” *Progress in Cardiovascular Diseases*, vol. 63, no. 3, pp. 390–391, 2020.

[50] M. Barnes, A. E. Heywood, A. Mahimbo, B. Rahman, A. T. Newall, and C. R. Macintyre, “Acute myocardial infarction and influenza: a meta-analysis of case-control studies,” *Heart*, vol. 101, no. 21, pp. 1738–1747, 2015.

[51] D. Chang, M. Saleh, Y. Garcia-Bengo, E. Choi, L. Epstein, and J. Willner, “COVID-19 infection unmasking Brugada syndrome,” *Heart Rhythm Case Reports*, vol. 6, no. 5, pp. 237–240, 2020.

[52] M. I. Vidovich, “Transient Brugada-Like Electrocardiographic Pattern in a Patient With COVID-19,” *JACC: Case Reports*, vol. 2, no. 9, pp. 1245–1249, 2020.

[53] G. Mahadeviah, A. Áleem, A. Secaira, S. Saha, and N. Shariff, “ST elevation in a patient with COVID-19 infection-associated fever: a case of Brugada pattern,” *Cureus*, vol. 12, article e8722, 2020.

[54] T. Asif and Z. Ali, “Transient ST segment elevation in two patients with COVID-19 and a normal transthoracic echocardiogram,” *European Journal of Case Reports in Internal Medicine*, vol. 7, no. 5, article 001672, 2020.

[55] A. Sorgente, L. Capulzini, and P. Brugada, “The known into the unknown: Brugada syndrome and COVID-19,” *JACC: Case Reports*, vol. 2, no. 9, pp. 1250–1251, 2020.

[56] Q. Ruan, K. Yang, W. Wang, L. Jiang, and J. Song, “Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China,” *Intensive Care Medicine*, vol. 46, no. 5, pp. 846–848, 2020.

[57] S. Shi, M. Qin, B. Shen et al., “Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China,” *JAMA Cardiology*, vol. 5, no. 7, pp. 802–810, 2020.

[58] P. E. Lazzerini, M. Boutjdir, and P. L. Capeccchi, “COVID-19, arrhythmic risk and inflammation: mind the gap!,” *Circulation*, vol. 142, no. 1, pp. 7–9, 2020.

[59] M. Bansal, “Cardiovascular disease and COVID-19,” *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, vol. 14, no. 3, pp. 247–250, 2020.

[60] G. Cimino, G. Pascarello, N. Bernardi et al., “Sinus node dysfunction in a young patient with COVID-19,” *JACC: Case Reports*, vol. 2, no. 9, pp. 1240–1244, 2020.

[61] G. Peigh, M. Leya, J. Baman, E. Cantey, B. Knight, and J. Flaherty, “Novel coronavirus 19 (COVID-19) associated sinus node dysfunction: a case series,” *European Heart Journal - Case Reports*, vol. 4, no. F11, pp. 1–6, 2020.

[62] S. M. Kochav, E. Coromilas, A. Nalbandian et al., “Cardiac arrhythmias in COVID-19 infection,” *Circulation. Arrhythmia and Electrophysiology*, vol. 13, no. 6, article e008719, 2020.

[63] T. J. Guzik, S. A. Mohiddin, A. Dimarco et al., “COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options,” *Cardiovascular Research*, vol. 116, no. 10, pp. 1666–1687, 2020.

[64] D. M. Roden, “A current understanding of drug-induced QT prolongation and its implications for anticancer therapy,” *Cardiovascular Research*, vol. 115, no. 5, pp. 895–903, 2019.

[65] C. I. Wu, P. G. Postema, E. Arbelo et al., “SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes,” *Heart Rhythm*, vol. 17, no. 9, pp. 1456–1462, 2020.

[66] M. Saleh, J. Gabriels, D. Chang et al., “Effect of chloroquine, hydroxychloroquine, and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection,” *Circulation. Arrhythmia and Electrophysiology*, vol. 13, no. 6, article e008662, 2020.

[67] E. Baldi, G. M. Sechi, C. Mare et al., “COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests,” *European Heart Journal*, vol. 41, no. 32, pp. 3045–3054, 2020.

[68] P. S. Chan, S. Girotra, Y. Tang, R. Al-Araj, B. K. Nallamothu, and B. McNally, “Outcomes for out-of-hospital cardiac arrest in the United States during the coronavirus disease 2019 pandemic,” *JAMA Cardiology*, vol. 6, no. 3, pp. 296–303, 2021.

[69] S. Ghio, E. Baldi, A. Vicentini et al., “Cardiac involvement at presentation in patients hospitalized with COVID-19 and their outcome in a tertiary referral hospital in northern Italy,” *Internal and Emergency Medicine*, vol. 15, no. 8, pp. 1457–1465, 2020.

[70] E. Baldi, G. M. Sechi, C. Mare et al., “Treatment of out-of-hospital cardiac arrest in the COVID-19 era: a 100 days experience from the Lombardy region,” *PLoS One*, vol. 15, no. 10, article e0241028, 2020.

[71] E. Marijon, N. Karam, D. Jost et al., “Out-of-hospital cardiac arrest during the COVID-19 pandemic in Paris, France: a population-based, observational study,” *The Lancet Public Health*, vol. 5, no. 8, pp. e437–e443, 2020.

[72] P. H. Lai, E. A. Lancet, M. D. Weiden et al., “Characteristics associated with out-of-hospital cardiac arrests and resuscitations during the novel coronavirus disease 2019 pandemic in New York City,” *JAMA Cardiology*, vol. 5, no. 10, pp. 1154–1163, 2020.

[73] E. Baldi, All the Lombardia CArE researchers, R. Primi et al., “Out-of-hospital cardiac arrest incidence in the different phases of COVID-19 outbreak,” *Resuscitation*, vol. 159, pp. 115–116, 2021.

[74] F. Zhou, T. Yu, R. du et al., “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study,” *Lancet*, vol. 395, no. 10229, pp. 1054–1062, 2020.
[75] M. Arentz, E. Yim, L. Klaff et al., "Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state," Journal of the American Medical Association, vol. 323, no. 16, pp. 1612–1614, 2020.

[76] C. Creel-Bulos, M. Hockstein, N. Amin, S. Melhem, A. Truong, and M. Sharifpour, "Acute cor pulmonale in critically ill patients with covid-19," The New England Journal of Medicine, vol. 382, no. 21, article e70, 2020.

[77] X. Lu, L. Zhang, H. du et al., "SARS-CoV-2 infection in children," The New England Journal of Medicine, vol. 382, no. 17, pp. 1663–1665, 2020.

[78] J. S. Chiu, M. Lahoud-Rahme, D. Schaffer, A. Cohen, and M. Samuels-Kalow, "Kawasaki disease features and myocardi- ditis in a patient with COVID-19," Pediatric Cardiology, vol. 41, no. 7, pp. 1526–1528, 2020.

[79] B. F. Printz, L. A. Sleeper, J. W. Newburger et al., "Noncorony cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease," Journal of the American College of Cardiology, vol. 57, no. 1, pp. 86–92, 2011.

[80] F. A. Klok, M. Kruij, N. J. M. van der Meer et al., "Incidence of thrombotic complications in critically ill ICU patients with COVID-19," Thrombosis Research, vol. 191, pp. 145–147, 2020.

[81] E. Droesch, M. Hoang, M. DeSancho, E. Lee, C. Magro, and J. Harp, "Livedoed and purpuric skin eruptions associated with coagulopathy in severe COVID-19," JAMA Dermatology, vol. 156, no. 9, pp. 1–3, 2020.

[82] G. Singh, H. Attique, N. Gadela, K. Mapara, and S. Manickaratnam, "COVID-19 related arterial coagulopathy," Cureus, vol. 12, article e9490, 2020.

[83] C. Galván Casas, A. Catalá, G. Carretero Hernández et al., "Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases," The British Journal of Dermatology, vol. 183, no. 1, pp. 71–77, 2020.

[84] L. Mao, H. Jin, M. Wang et al., "Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China," vol. 77, Tech. Rep. 6, JAMA Neurol, 2020.

[85] Y. Zhang, M. Xiao, S. Zhang et al., "Coagulopathy and anti-phospholipid antibodies in patients with covid-19," The New England Journal of Medicine, vol. 382, no. 17, article e38, 2020.

[86] T. Iba, J. H. Levy, J. M. Connors, T. E. Warkentin, J. Thachil, and M. Levi, "The unique characteristics of COVID-19 coagulopathy," Critical Care, vol. 24, no. 1, p. 360, 2020.

[87] G. Lippi, M. Plebani, and B. M. Henry, "Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis," Clinica Chimica Acta, vol. 506, pp. 145–148, 2020.

[88] G. Zhang, J. Zhang, B. Wang, X. Zhu, Q. Wang, and S. Qiu, "Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis," Respiratory Research, vol. 21, no. 1, p. 74, 2020.

[89] N. Chen, M. Zhou, X. Dong et al., "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study," Lancet, vol. 395, no. 10223, pp. 507–513, 2020.

[90] I. W. Uthman and A. E. Ghavari, "Viral infections and anti-phospholipid antibodies," Seminars in Arthritis and Rheumatism, vol. 31, no. 4, pp. 256–263, 2002.

[91] M. B. Pepys and G. M. Hirschfield, "C-reactive protein: a critical update," The Journal of Clinical Investigation, vol. 111, no. 12, pp. 1805–1812, 2003.

[92] G. Yaron, A. Brill, O. Dashevsky et al., "C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway in atherothrombosis," British Journal of Haematology, vol. 134, no. 4, pp. 426–431, 2006.

[93] C. Bryce, Z. Grimes, E. Pujadas et al., "Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience," medRxiv, 2020.

[94] S. F. Lax, K. Skok, P. Zechn et al., "Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series," Annals of Internal Medicine, vol. 173, no. 5, pp. 350–361, 2020.

[95] S. E. Fox, A. Akmatbekov, J. L. Harbert, G. Li, J. Quincy Brown, and R. S. Vander Heide, "Pulmonary and cardiac pathologic in African American patients with COVID-19: an autopsy series from New Orleans," The Lancet Respiratory Medicine, vol. 8, no. 7, pp. 681–686, 2020.

[96] B. T. Bradley, H. Maioli, R. Johnston et al., "Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series," Lancet, vol. 396, no. 10247, pp. 320–322, 2020.

[97] C. Edler, A. S. Schröder, M. Aepfelbacher et al., "Dying with SARS-CoV-2 infection—an autopsy study of the first consecutive 80 cases in Hamburg, Germany," International Journal of Legal Medicine, vol. 134, no. 4, pp. 1275–1284, 2020.

[98] K. Wichmann, J. P. Sperhake, M. Lütgethetmann et al., "Autopsy findings and venous thromboembolism in patients with COVID-19," Annals of Internal Medicine, vol. 173, no. 4, pp. 268–277, 2020.

[99] Z. Varga, A. J. Flammer, P. Steiger et al., "Endothelial cell infection and endothelitis in COVID-19," Lancet, vol. 395, no. 10234, pp. 1417–1418, 2020.

[100] A. V. Rapkiewicz, X. Mai, S. E. Carson et al., "Mega- karyocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series," EClinical-Medicine, vol. 24, p. 100434, 2020.

[101] V. G. Puelles, M. Lütgethetmann, M. T. Lindenmeyer et al., "Multiorgan and renal tropism of SARS-CoV-2," The New England Journal of Medicine, vol. 383, no. 6, pp. 590–592, 2020.

[102] R. Bussani, E. Schneider, L. Zentilin et al., "Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology," EBioMedicine, vol. 61, article 103104, 2020.

[103] G. Tavazzi, C. Pellegrini, M. Maurelli et al., "Myocardial localization of coronavirus in COVID-19 cardiogenic shock," European Journal of Heart Failure, vol. 22, no. 5, pp. 911–915, 2020.

[104] P. Wenzel, S. Kopp, S. Gobel et al., "Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab," Cardiovascular Research, vol. 116, no. 10, pp. 1661–1663, 2020.

[105] R. M. Inciardi, L. Lupi, G. Zacccone et al., "Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)," JAMA Cardiology, vol. 5, no. 7, pp. 819–824, 2020.
M. Rehman, A. Gondal, and N. U. Rehman, “Atypical manifestation of COVID-19-induced myocarditis,” Cureus, vol. 12, article e8685, 2020.

J. A. Fried, K. Ramasubbu, R. Bhatt et al., “The variety of cardiovascular presentations of COVID-19,” Circulation, vol. 141, no. 23, pp. 1930–1936, 2020.

V. O. Puntmann, M. L. Carerj, I. Wieters et al., “Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19),” JAMA Cardiology, vol. 5, no. 11, pp. 1265–1273, 2020.

V. F. Corrales-Medina, K. N. Alvarez, L. A. Weissfeld et al., “Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease,” Journal of the American Medical Association, vol. 313, no. 3, pp. 264–274, 2015.

R. D. Mitrani, N. Dabas, and J. J. Goldberger, “COVID-19 cardiac injury: implications for long-term surveillance and outcomes in survivors,” Heart Rhythm, vol. 17, no. 11, pp. 1984–1990, 2020.

S. Rajpal, M. S. Tong, J. Borchers et al., “Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection,” JAMA Cardiology, vol. 6, no. 1, pp. 116–118, 2021.

K. Mangion, A. Morrow, C. Bagot et al., “The chief scientist office cardiovascular and pulmonary imaging in SARS coronavirus disease-19 (CISCO-19) study,” Cardiovascular Research, vol. 116, no. 14, pp. 2185–2196, 2020.

S. Richardson, J. S. Hirsch, M. Narasimhan et al., “Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area,” Journal of the American Medical Association, vol. 323, no. 20, pp. 2052–2059, 2020.

P. K. Bhatraju, B. J. Ghassemieh, M. Nichols et al., “Covid-19 in critically ill patients in the Seattle region - case series,” The New England Journal of Medicine, vol. 382, no. 21, pp. 2012–2022, 2020.

L. Wang, W. He, X. Yu et al., “Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up,” The Journal of Infection, vol. 80, no. 6, pp. 639–645, 2020.

W. J. Guan, Z. Y. Ni, Y. Hu et al., “Clinical characteristics of coronavirus disease 2019 in China,” The New England Journal of Medicine, vol. 382, no. 18, pp. 1708–1720, 2020.

C. Huang, Y. Wang, X. Li et al., “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” Lancet, vol. 395, no. 10223, pp. 497–506, 2020.

M. Grimaud, J. Starck, M. Levy et al., “Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children,” Annals of Intensive Care, vol. 10, no. 1, p. 69, 2020.

G. G. Stefanini, M. Montorfano, D. Trabattoni et al., “ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes,” Circulation, vol. 141, no. 25, pp. 2113–2116, 2020.

H. Yang, L. C. Yang, R. T. Zhang, Y. P. Ling, and Q. G. Ge, “Risks factors for death among COVID-19 patients combined with hypertension, coronary heart disease or diabetes,” Beijing Da Xue Xue Bao. Yi Xue Ban, vol. 52, no. 3, pp. 420–424, 2020.

S. Tian, Y. Xiong, H. Liu et al., “Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies,” Modern Pathology, vol. 33, no. 6, pp. 1007–1014, 2020.